On November 5, 2024, the VIVA Foundation reported on presentations at the VIVA25 conference, including two-year results of the DEEPER OUS clinical trial for the Reflow Medical Spur® Peripheral Retrievable…
Read More
Updates on Spur® Retrievable Scaffold Therapy (RST) at AMP At the Amputation Prevention Symposium (AMP) held in Chicago in August, S. Jay Mathews, MD, provided an excellent review: “Retrievable Stent…
Enrollment Completed in the DEEPER REVEAL Clinical Trial We want to thank everyone who worked to complete enrollment in the DEEPER REVEAL clinical trial (NCT05358353) to evaluate Spur™ Retrievable Scaffold…
San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of…
San Clemente, CA – May 08, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces completion of enrollment in the DEEPER REVEAL clinical trial…
CE Mark Certification for the Bare Temporary Spur Stent System Reflow has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System for…
San Clemente, CA—Jan. 15, 2024 – Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the…
SAN CLEMENTE, CA — November 6, 2023 — Reflow Medical announced one-year results of the DEEPER OUS clinical trial (NCT04162418) evaluating the company’s Bare Temporary Spur Stent System. Results were…
Expanding into Complex Percutaneous Coronary Interventions (PCI) with the introduction of the coraCatheters™ line We are proud to announce that we received FDA commercial clearance for our new coraCatheters…
SAN CLEMENTE, Calif. – – June 12, 2023 – – Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of…
Recent Comments